Octreotide Administration Methods in Sulfonylurea Poisoning: A Retrospective Chart Review.
In patients with sulfonylurea-induced hypoglycemia, intravenous infusion of octreotide may lead to more hypoglycemic events compared to bolus or subcutaneous administration.
Where it sits
this study against the rest of the octreotide corpusSummary and findings
This study evaluated the effectiveness of different octreotide administration methods in patients with sulfonylurea-induced hypoglycemia. The routes compared were intravenous bolus, intravenous infusion, and subcutaneous administration. The primary outcome measured was the number of hypoglycemic events following octreotide initiation.
Abstract
<h4>Introduction</h4>Octreotide is used to treat sulfonylurea induced hypoglycemia, but the effectiveness of intravenous bolus, intravenous infusion, and subcutaneous routes of octreotide administration has not been compared.<h4>Methods</h4>This is a multi-center, retrospective chart review of patients with suspected sulfonylurea induced hypoglycemia who received octreotide, comparing intravenous bolus, intravenous infusion, and/or subcutaneous routes of octreotide administration. The primary outcome was number of hypoglycemic events after octreotide initiation. Secondary outcomes included total octreotide dose, dextrose administered before and after first octreotide dose, and hospital length of stay.<h4>Results</h4>Of 29 included cases, the intravenous bolus group had 10 patients, intravenous infusion group had four patients, and the subcutaneous group had 15 patients. Median post-octreotide hypoglycemic events were zero, 1.5, and zero for bolus, infusion, and subcutaneous groups, respectively. Median total octreotide dose was 50 mcg [IQR: 49 - 100 mcg], 693 mcg [IQR: 402 - 939 mcg], and 100 mcg [IQR: 50 - 150 mcg] for bolus, infusion, and subcutaneous groups, respectively. The bolus (115 grams [41 - 152 grams]) and subcutaneous groups (80 grams [53 - 189 grams]) received less post-octreotide dextrose than the infusion group (256 grams [86 - 560 grams]). Median length was 40, 60, and 62 hours between the bolus, infusion, and subcutaneous groups, respectively.<h4>Conclusion</h4>The infusion group had a higher incidence of hypoglycemia and received more post-octreotide dextrose than intravenous bolus or subcutaneous groups, despite a larger total octreotide dose. These findings suggest octreotide infusions may be inferior, but further studies are needed to determine the optimal octreotide administration route for sulfonylurea induced hypoglycemia.
Background
This paper addresses the clinical question of how different administration methods of octreotide affect outcomes in sulfonylurea-induced hypoglycemia. Previous knowledge indicates that octreotide is used to manage hypoglycemia caused by sulfonylureas, but there has been no comparative analysis of administration routes. Understanding the effectiveness of these methods is crucial for optimizing treatment protocols.
Methods
This study utilized a multi-center, retrospective chart review design. The population included patients with suspected sulfonylurea-induced hypoglycemia who received octreotide. A total of 29 cases were included, with 10 in the intravenous bolus group, 4 in the intravenous infusion group, and 15 in the subcutaneous group. The primary outcome was the number of hypoglycemic events after octreotide initiation, with secondary outcomes including total octreotide dose, dextrose administered, and hospital length of stay.
Results
The primary endpoint showed that median post-octreotide hypoglycemic events were zero for the bolus group, 1.5 for the infusion group, and zero for the subcutaneous group. The median total octreotide doses were 50 mcg [IQR: 49 - 100 mcg] for bolus, 693 mcg [IQR: 402 - 939 mcg] for infusion, and 100 mcg [IQR: 50 - 150 mcg] for subcutaneous. The infusion group received significantly more dextrose (256 grams [86 - 560 grams]) compared to the bolus (115 grams [41 - 152 grams]) and subcutaneous groups (80 grams [53 - 189 grams]). Median lengths of stay were 40 hours for bolus, 60 hours for infusion, and 62 hours for subcutaneous.
Interpretation
The findings suggest that the intravenous infusion of octreotide may be associated with a higher incidence of hypoglycemia despite a larger total dose, which raises questions about its effectiveness compared to bolus or subcutaneous administration. While the differences in hypoglycemic events are statistically significant, the clinical relevance of these findings remains uncertain due to the small sample size and retrospective nature of the study. Further research is needed to clarify the optimal route of administration for clinical practice.
Key findings
- Median post-octreotide hypoglycemic events were zero for bolus, 1.5 for infusion, and zero for subcutaneous groups.
- Median total octreotide dose was 50 mcg [IQR: 49 - 100 mcg] for bolus, 693 mcg [IQR: 402 - 939 mcg] for infusion, and 100 mcg [IQR: 50 - 150 mcg] for subcutaneous groups.
- The bolus group received 115 grams [41 - 152 grams] of dextrose post-octreotide, while the infusion group received 256 grams [86 - 560 grams].
- Median length of stay was 40 hours for bolus, 60 hours for infusion, and 62 hours for subcutaneous groups.
Limitations
- small n=29 cases
- retrospective design
- single-center data may limit generalizability
- no randomization or blinding